Tumor-suppressing viruses, genes, and drugs : innovative cancer therapy approaches

著者

• Maruta, Hiroshi

書誌事項

Tumor-suppressing viruses, genes, and drugs : innovative cancer therapy approaches

edited by Hiroshi Maruta

Academic Press, c2002

注記

Includes bibliographical references and index

HTTP:URL=http://www.loc.gov/catdir/description/els031/2001095847.html Information=Publisher description

内容説明・目次

内容説明

Tumor Suppressing Viruses, Genes, and Drugs profiles the new generation of cancer treatments now in development. The book examines the innovative new approaches of viral, gene, and signal therapies that promise to replace or enhance conventional methods such as surgery, radiation, and chemotherapy. The timely information presented by this book should be of interest to anyone concerned with advancing cancer treatment beyond current medical practices.

目次

Contributors Preface 1 Oncolytic Viruses: Virotherapy for Cancer I. Introduction II. Attributes of Replication-Selective Viruses for Cancer Treatment III. Approaches to Optimizing Tumor-Selective Viral Replication IV. Adenoviruses V. Poliovirus VI. Vesicular Stomatitis Virus VII. Reovirus VIII. Bacteria IX. Vaccinia Virus X. Herpesvirus XI. Clinical Trial Results with Replication-Competent Adenoviruses in Cancer Patients XII. Results from Clinical Trials with dl1520 (Onyx-015, or CI-1042) XIII. Future Directions: Approaches to Improving the Efficacy of Replication-Selective Viral Agents XIV. Summary References 2 Reovirus Therapy of Ras-Associated Cancers I. Introduction II. Reovirus Oncolysis III. Concluding Remarks References 3 Oncolytic Herpes Simplex Virus (G207) Therapy: From Basic to Clinical I. Introduction II. Preclinical Studies of G207 III. G207 Clinical Trial IV. Conclusions References 4 p53 and Its Targets I. Introduction II. Activation of p53 III. Downstream Mediators of p53 References 5 Prospects for Tumor Suppressor Gene Therapy: RB as an Example I. Introduction II. Functions of RB III. Successes with RB Gene Therapy IV. Perspectives References 6 CDK Inhibitors: Genes and Drugs I. Introduction II. G1 Regulation III. p16INK4a and the Rb Pathway IV. p19ARF and p53 Pathway V. p27 and Human Cancer VI. Conclusions and Future Perspectives References 7 CDK Inhibitors: Small Molecular Weight Compounds I. Introduction II. Cyclin-Dependent Kinases, the Cell Cycle, and Cancer III. Cyclin-Dependent Kinase Inhibitors, a Large Variety of Structures IV. Cyclin-Dependent Kinase Inhibitors, All Competing with ATP V. Cyclin-Dependent Kinase Inhibitors, the Selectivity Problem VI. Cyclin-Dependent Kinase Inhibitors, Cellular Effects VII. Cyclin-Dependent Kinase Inhibitors, Antitumor Activity VIII. Conclusion References 8 NF1 and Other RAS-Binding Peptides I. RAS Molecules: Normal versus Oncogenic Mutants II. Super GAP? III. RAS-Binding Fragment of NF1 IV. c-RAF-1 V. PI-3 Kinase VI. Ral GDS References 9 Cytoskeletal Tumor Suppressor Genes I. Introduction (Historical Background) II. Type I Cytoskeletal Tumor Suppressors III. Type II Cytoskeletal Tumor Suppressors References 10 TGF-? Signaling and Carcinogenesis I. Introduction II. Dual Role of TGF-? in Carcinogenesis III. TGF-? Superfamily Signaling IV. Perturbation of TGF-? Signaling in Cancer Cells V. Perspectives References 11 DAN Gene I. Introduction II. Cloning of DAN cDNA III. Transfection of DAN IV. Role of DAN in Neuroblastomas V. Structural Features of the DAN Protein VI. Genomic Structure of DAN VII. DAN Family References 12 Design of Hammerhead Ribozymes and Allosterically Controllable Maxizymes for Cancer Gene Therapy I. Introduction II. Ribozyme Expression System in Cells III. Design of the tRNAVal-Driven Ribozyme That Is Transcribed by pol III IV. Design of Allosterically Controlled Maxizymes V. Conclusion References 13 Inhibitors of Angiogenesis I. Introduction-Angiogenesis II. Angiogenesis Inhibitors III. Future Directions References 14 Geranylgeranylated RhoB Mediates the Apoptotic and Antineoplastic Effects of Farnesyltransferase Inhibitors: New Insights into Cancer Cell Suicide I. Introduction II. Do Farnesyltransferase Inhibitors Target a Unique Aspect of Neoplastic Pathophysiology? III. Ras Is Not a Crucial Target of Farnesyltransferase Inhibitors IV. RhoB Is a Crucial Target of Farnesyltransferase Inhibitors V. Farnesyltransferase Inhibitors Act through a Gain of Function Mechanism Involving RhoB-GG VI. RhoB-GG Is Required to Mediate Apoptosis by Farnesyltransferase Inhibitors VII. RhoB-GG and the Antiangiogenic Properties of Farnesyltransferase Inhibitors VIII. Clinical Implications IX. Summary References 15 RAS Binding Compounds I. Introduction II. Ras Cycle and Ras-Raf Signaling Pathway III. The Structure of Ras Proteins IV. Drug Target Sites of Ras V. Conclusions and Outlook References 16 Actin-Binding Drugs: MKT-077 and Chaetoglobosin K (CK) I. Introduction II. MKT-077: F-Actin Bundler III. Chaetoglobosin K: F-Actin Capper References 17 Tyr Kinase Inhibitors as Potential Anticancer Agents: EGF Receptor and ABL Kinases I. Introduction II. Tyr Kinase Inhibitors III. Chronic Myelogenous Leukemia IV. Epidermal Growth Factor Receptor V. Antagonists of the Epidermal Growth Factor Receptor Extracellular Domain VI. Chemical Inhibitors of the Kinase Domain of the Epidermal Growth Factor Receptor VII. Epidermal Growth Factor Receptor Antagonists or Inhibitors Act Synergistically to Kill Tumor Cells VIII. The Effects of Abl Inhibitors on Leukemia References 18 Antagonists of Rho Family GTPases: Blocking PAKs, ACKs, and Rock I. Rho Family GTPases (Rho, Rac, and CDC42) II. Blocking PAKs III. Blocking CDC42 Pathways (ACKs and N-WASP) IV. Blocking Rho Pathways V. Rac-Specific Inhibitors? References 19 Integrin Antagonists as Cancer Therapeutics I. Introduction II. Signaling Pathways Activated by Integrins InII. Role of Integrins in Neoplastic Transformatio IV. Role of Integrins in Tumor-Induced Angiogenesis V. Integrin Antagonists as Antiangiogenesis Agents VI. Conclusions and Future Perspectives References 20 Functional Rescue of Mutant p53 as a Strategy to Combat Cancer I. Introduction II. Multiple Pathways of p53-Induced Apoptosis III. Regulation of p53 Activity IV. Approaches toward Reactivation of Mutant p53 V. Implications for Tumor Therapy and Future Perspectives References Index

「Nielsen BookData」 より

詳細情報

• NII書誌ID(NCID): BA69796738
• ISBN:
  • 0124762492
• LCCN: 2001095847
• 出版国コード: us
• タイトル言語コード: eng
• 本文言語コード: eng
• 出版地: San Diego
• ページ数/冊数: xv, 425 p.
• 大きさ: 24 cm
• 分類:
  • LCC : RC268.43
  • DC21 : 616.99/406
• 件名:
  • LCSH : Antioncogenes
  • LCSH : Cancer -- Gene therapy
  • LCSH : Viruses -- Therapeutic use
  • LCSH : Cancer -- Treatment -- Technological innovations
  • LCSH : Cancer -- Molecular aspects